Skip to main content
Erschienen in: World Journal of Urology 3/2018

14.12.2017 | Original Article

Retrospective analysis of the development of PIRADS 3 lesions over time: when is a follow-up MRI reasonable?

verfasst von: Fabian Steinkohl, Leonhard Gruber, Jasmin Bektic, Udo Nagele, Friedrich Aigner, Thomas R. W. Herrmann, Michael Rieger, Daniel Junker

Erschienen in: World Journal of Urology | Ausgabe 3/2018

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Often PIRADS 3 findings are usually followed up with further MRIs of the prostate. Current guidelines do not state an optimal interval between the initial MRI and the follow-up MRI. The aim of this study was to find out if PIRADS 3 lesions evolve over time and to determine how long the optimal interval between initial MRI and follow-ups should be.

Methods

In this retrospective study, 141 consecutive patients were included who underwent at least one follow-up MRI after an initial PIRADS 3 finding. Changes in PIRADS score and the interval between the first and the follow-up MRI were recorded. An optimal duration was calculated.

Results

Of all patients, 76.6% had a change from PIRADS 3 to either 2 or 4 in the first follow-up MRI. Reclassifications to PIRADS 4 happened earlier than reclassifications to PIRADS 2 (after 366.5 ± 217.9 days and after 534.2 ± 253.0 days, respectively). An optimal point of time for a follow-up to distinguish between changes to PIRADS 2 versus PIRADS 4 turned out to be 379 days (12.4 months, AUC 0.734, p = 0.0001). Of all patients with a PIRADS 3 lesion 14.8% harboured a prostate carcinoma.

Conclusion

Performing follow-up mpMRI rather than immediate biopsy may be beneficial for patients with PIRADS 3, as most lesions can be reclassified after a manageable period of time. Upgrades to PIRADS 4 seem to happen earlier and within fewer follow-ups than downgrades to PIRADS 2. The optimal interval for follow-up MRIs seems to be 12.4 months.
Literatur
6.
8.
Zurück zum Zitat Roehl KA, Antenor JA, Catalona WJ (2002) Serial biopsy results in prostate cancer screening study. J Urol 167(6):2435–2439CrossRefPubMed Roehl KA, Antenor JA, Catalona WJ (2002) Serial biopsy results in prostate cancer screening study. J Urol 167(6):2435–2439CrossRefPubMed
11.
Zurück zum Zitat Thompson JE, Moses D, Shnier R, Brenner P, Delprado W, Ponsky L, Pulbrook M, Bohm M, Haynes AM, Hayen A, Stricker PD (2014) Multiparametric magnetic resonance imaging guided diagnostic biopsy detects significant prostate cancer and could reduce unnecessary biopsies and over detection: a prospective study. J Urol 192(1):67–74. https://doi.org/10.1016/j.juro.2014.01.014 CrossRefPubMed Thompson JE, Moses D, Shnier R, Brenner P, Delprado W, Ponsky L, Pulbrook M, Bohm M, Haynes AM, Hayen A, Stricker PD (2014) Multiparametric magnetic resonance imaging guided diagnostic biopsy detects significant prostate cancer and could reduce unnecessary biopsies and over detection: a prospective study. J Urol 192(1):67–74. https://​doi.​org/​10.​1016/​j.​juro.​2014.​01.​014 CrossRefPubMed
12.
Zurück zum Zitat Pokorny MR, de Rooij M, Duncan E, Schroder FH, Parkinson R, Barentsz JO, Thompson LC (2014) Prospective study of diagnostic accuracy comparing prostate cancer detection by transrectal ultrasound-guided biopsy versus magnetic resonance (MR) imaging with subsequent MR-guided biopsy in men without previous prostate biopsies. Eur Urol 66(1):22–29. https://doi.org/10.1016/j.eururo.2014.03.002 CrossRefPubMed Pokorny MR, de Rooij M, Duncan E, Schroder FH, Parkinson R, Barentsz JO, Thompson LC (2014) Prospective study of diagnostic accuracy comparing prostate cancer detection by transrectal ultrasound-guided biopsy versus magnetic resonance (MR) imaging with subsequent MR-guided biopsy in men without previous prostate biopsies. Eur Urol 66(1):22–29. https://​doi.​org/​10.​1016/​j.​eururo.​2014.​03.​002 CrossRefPubMed
15.
Zurück zum Zitat Felker ER, Raman SS, Margolis DJ, Lu DSK, Shaheen N, Natarajan S, Sharma D, Huang J, Dorey F, Marks LS (2017) Risk stratification among men with prostate imaging reporting and data system version 2 category 3 transition zone lesions: is biopsy always necessary? AJR Am J Roentgenol 31:1–6. https://doi.org/10.2214/AJR.17.18008 Felker ER, Raman SS, Margolis DJ, Lu DSK, Shaheen N, Natarajan S, Sharma D, Huang J, Dorey F, Marks LS (2017) Risk stratification among men with prostate imaging reporting and data system version 2 category 3 transition zone lesions: is biopsy always necessary? AJR Am J Roentgenol 31:1–6. https://​doi.​org/​10.​2214/​AJR.​17.​18008
17.
Zurück zum Zitat Siddiqui MM, Rais-Bahrami S, Truong H, Stamatakis L, Vourganti S, Nix J, Hoang AN, Walton-Diaz A, Shuch B, Weintraub M, Kruecker J, Amalou H, Turkbey B, Merino MJ, Choyke PL, Wood BJ, Pinto PA (2013) Magnetic resonance imaging/ultrasound-fusion biopsy significantly upgrades prostate cancer versus systematic 12-core transrectal ultrasound biopsy. Eur Urol 64(5):713–719. https://doi.org/10.1016/j.eururo.2013.05.059 CrossRefPubMed Siddiqui MM, Rais-Bahrami S, Truong H, Stamatakis L, Vourganti S, Nix J, Hoang AN, Walton-Diaz A, Shuch B, Weintraub M, Kruecker J, Amalou H, Turkbey B, Merino MJ, Choyke PL, Wood BJ, Pinto PA (2013) Magnetic resonance imaging/ultrasound-fusion biopsy significantly upgrades prostate cancer versus systematic 12-core transrectal ultrasound biopsy. Eur Urol 64(5):713–719. https://​doi.​org/​10.​1016/​j.​eururo.​2013.​05.​059 CrossRefPubMed
19.
Zurück zum Zitat Schoots IG, Roobol MJ, Nieboer D, Bangma CH, Steyerberg EW, Hunink MG (2015) Magnetic resonance imaging-targeted biopsy may enhance the diagnostic accuracy of significant prostate cancer detection compared to standard transrectal ultrasound-guided biopsy: a systematic review and meta-analysis. Eur Urol 68(3):438–450. https://doi.org/10.1016/j.eururo.2014.11.037 (Epub 2014 Dec 3) CrossRefPubMed Schoots IG, Roobol MJ, Nieboer D, Bangma CH, Steyerberg EW, Hunink MG (2015) Magnetic resonance imaging-targeted biopsy may enhance the diagnostic accuracy of significant prostate cancer detection compared to standard transrectal ultrasound-guided biopsy: a systematic review and meta-analysis. Eur Urol 68(3):438–450. https://​doi.​org/​10.​1016/​j.​eururo.​2014.​11.​037 (Epub 2014 Dec 3) CrossRefPubMed
Metadaten
Titel
Retrospective analysis of the development of PIRADS 3 lesions over time: when is a follow-up MRI reasonable?
verfasst von
Fabian Steinkohl
Leonhard Gruber
Jasmin Bektic
Udo Nagele
Friedrich Aigner
Thomas R. W. Herrmann
Michael Rieger
Daniel Junker
Publikationsdatum
14.12.2017
Verlag
Springer Berlin Heidelberg
Erschienen in
World Journal of Urology / Ausgabe 3/2018
Print ISSN: 0724-4983
Elektronische ISSN: 1433-8726
DOI
https://doi.org/10.1007/s00345-017-2135-0

Weitere Artikel der Ausgabe 3/2018

World Journal of Urology 3/2018 Zur Ausgabe

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.